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Teaser 
A large thermodynamic dataset from Astex, AstraZeneca, Pfizer and academic labs which includes 
fragment-protein interactions demonstrates that, when compared to many traditional drug-like 
compounds, fragments bind more enthalpically to their protein targets. 
  
Abstract 
Small is beautiful – reducing the size and complexity of chemical starting points for drug design 
allows better sampling of chemical space, reveals the most energetically important interactions 
within protein binding sites and can lead to improvements in the physico-chemical properties of the 
final drug.  The impact of fragment based drug discovery (FBDD) on recent drug discovery projects 
and our improved knowledge of the structural and thermodynamic details of ligand binding has 
prompted us to explore the relationships between ligand binding thermodynamics and FBDD. 
Information on binding thermodynamics can give insights into the contributions to protein-ligand 
interactions and may therefore be used to prioritise compounds with a high degree of specificity in 
forming key interactions.  
 
Ligand size and binding thermodynamics 
The maximal available binding affinity depends on ligand size and this observation appears to 
support the medicinal chemistry practice that adds new functional groups in order to improve 
affinity. In contrast, it has been claimed that the maximal available enthalpy gain decreases with 
increasing ligand size or, viewed alternatively, that medicinal chemistry optimisation has traditionally 
tended to enhance affinity mainly for entropic reasons [1-3]. However, this may be an over-
simplification when considering the effects of small structural changes between similar ligands [4]. 
While high favourable enthalpy is accompanied by high affinity in the case of small ligands, this is not 
necessarily true for large ligands, where higher affinity compounds bind typically with lower enthalpy 
gain and further improvement in binding enthalpy is often achieved at the expense of affinity. These 
observations are based on the analysis of large, publically-available isothermal titration calorimetry 
(ITC) data sets, such as the Scorpio (URL: http://scorpio.biophysics.ismb.lon.ac.uk/scorpio.html), and 
BindingDB (URL: http://www.bindingdb.org/bind/index.jsp) databases. Since binding enthalpy 
broadly reflects the overall quality of protein-ligand interactions, the opposite size dependence of 
affinity and enthalpy may have fundamental consequences for drug-discovery practices, including 
the identification of chemical starting points and their optimization: (i) more enthalpic binders may 
prove to be more advantageous starting points for medicinal chemistry optimizations; (ii) enthalpic 
optimization may be more beneficial during the early phase of optimizations; and (iii) smaller 
compounds may be more likely  to bind enthalpically than larger compounds. 
The demonstrated success of fragment based drug discovery programs and the proposed 
consequences prompted us to investigate the binding of fragment-size compounds by analysing their 
complexes in the PDB [1]. It was found that fragments often form a small number (two on average) 
of near-to-optimal geometry H-bonds. This is a consequence of their small size that allows them to 
form good quality H-bonds with low steric constraints.  These usually contribute decisively to the 
binding free energy and this contribution is predominantly enthalpic, overcoming the loss of ligand 
rigid-body entropy that is also associated with binding. The complexity model of Hann [5] supports 
the view that ligands are able to form a limited number of optimal interactions and that their number 
does not increase with increasing ligand size and complexity. Indeed, it was found that the burial of 
50-100 Å2 polar surface area that can be associated with the formation of two H-bonds results in a 
significant enthalpic benefit but this benefit does not increase with increasing polar surface area 
burial [6]. 
Fragments usually bind to a confined region within a larger protein binding site and this is identified 
as the hot spot. Hot spots are energetically important regions of the binding site; they are able to 
bind a diverse set of small organic compounds [7,8], and they bind fragments in a way that the 
extension of the fragments to larger compounds does not affect the binding pose [9]. 
A consequence of the small size of fragments is that their binding to the hot spot disturbs the water 
network to a lesser extent and in a different manner than do large ligands. A particular feature of hot 
spots is that they are often associated with water molecules which have unfavourable excess entropy 
[10]. Using inhomogeneous fluid solvation theory Huggins estimated the enthalpic and entropic 
contributions of individual water molecules in 19 protein cavities of 5 proteins [11] and concluded 
that the contribution of entropic penalty of water molecules in protein cavities might be small to the 
free energy. These observations suggest that the small number of such water molecules released by 
fragment-binding is usually unable to turn the entropy balance. This is well illustrated by the binding 
of a series of fragments to carbonic anhydrase where the release of water molecules plays a decisive 
role in determining the relative enthalpy and entropy content of binding. Nevertheless, the overall 
contribution of water release to the binding enthalpy is a fraction of the observed enthalpy gain and 
does not affect the substantially favourable enthalpy [12].  
Apolar desolvation contributes to the binding of larger ligands and it was shown that the burial of 
~20 Å2 apolar Connolly surface upon binding typically leads to ~1 kJ.mol-1 free energy gain [6]. While 
this dominantly entropic contribution is significant for large ligands it is less important for fragments 
owing to their small size and buried surface. Moreover, the rigid body entropy loss upon ligand-
protein binding amounts to approximately 15-20 kJ.mol-1 [13] that must be compensated before 
entropically favoured binding is observed. This latter entropy loss only slightly increases with ligand 
size and for this reason its contribution is relatively more important for fragments than for larger 
ligands. 
The observations that fragments can achieve higher favourable binding enthalpy than larger ligands; 
that they can form optimal geometry H-bonds in the protein hot spot without incurring a large apolar 
desolvation penalty; and that this occurs without significantly disturbing the water network in the 
binding site, strongly suggest that fragments would be expected to bind enthalpically. 
 
Experimental thermodynamic data of fragment binding  
There is a large body of experimental evidence that is in line with the expectations discussed above; 
fragments bind to proteins with favourable enthalpy.  These data come most abundantly from direct 
measurements of enthalpy.  With recent methodological and technical developments [14], 
Isothermal Titration Calorimetry (ITC) experiments have become feasible for low affinity complexes, 
allowing the accurate measurement of significant enthalpies (|Hbinding|>5kJ.mol-1) for binding 
affinities in the range 100 μM < Kd < ~1 mM (‘low-c titrations’) and 10 nM < Kd < 100 μM for direct 
titrations [15].  
First we investigated the binding thermodynamics profile of fragments reported in the biomedical 
literature. Binding thermodynamic data of this set of diverse 284 fragments are shown in Figure 1 
panels A and B, and indicate that the majority of the fragments bind with a favourable enthalpy 
change [1]. The few exceptions found in the public dataset are all charged compounds and the 
observed entropy dominated binding is in line with the large enthalpic penalty of de-solvation for 
ions (Table 1). 
Figure 1 panel A gives a traditional representation of this thermodynamic binding data, where H is 
plotted against –TS.  Large areas of such graphs are empty, corresponding to complexes where the 
affinities are too weak to measure (G>0 kJ.mol-1) or too tight to achieve with typical non-covalent 
interactions (G<-60kJ.mol-1).   Data in Figure panel B and those in all subsequent figures are shown 
as G versus H+TS. This change of axes leads to a 45 rotation of the data when compared to the 
more usual representation of H versus -TS in panel A.  The quantity (-1/T).(H + TS) has a 
physical meaning, corresponding to the difference between the entropy created in the system (S) 
and outside the system (-H/T), for a closed system undergoing a spontaneous change.  Compounds 
with both favourable enthalpy and entropy appear in the lower-middle triangle while those with 
unfavourable enthalpy are above the right diagonal and those with unfavourable entropy are above 
the left diagonal.  Areas which contain no data points can be excluded by restricting the G axis 
scale.   
This representation also suggests the use of the ratio (H+TS)/G as a measure of the enthalpic 
driving force. This quantity is zero when enthalpy and entropy contribute equally to the free energy 
of binding and is positive for enthalpy-driven binding (H < -TS).   Its value exceeds 1 when enthalpy 
must overcompensate an unfavourable binding entropy (compounds above the left diagonal in 
Figure panel B).  By contrast, a negative value of the ratio indicates an entropy-driven binding while 
values smaller than -1 correspond to a favourable entropy that overcompensates an unfavourable 
enthalpy (compounds above the right diagonal of Figure 1 panel A).  
Consequently, we define the dimensionless ratio (H+TS)/G as the Enthalpy-Entropy Index (IE-E) 
and use it here to indicate the enthalpy content of binding. Its advantageous feature is that it is 
normalised by the free energy G (=H-TS), and so it can be used to compare compounds with 
millimolar to nanomolar binding affinities, during the course of a hits-to-leads optimisation. 
Thermodynamic binding data for a larger set of carefully selected fragments has been obtained at 
Astex and Astra-Zeneca, in the course of their drug discovery programs and is shown in Figure 1 
panel C. The Astex data shown in Figure 1 panel C includes a total of 782 ITC measurements obtained 
from fragment screening hits, optimized fragment hits, fragment-derived leads and optimized leads, 
binding to a diverse set of 24 target proteins. This dataset complements those from public sources 
and shows that an overwhelming majority of compounds (98.7%) investigated at Astex bind with 
favourable enthalpy. The best fit line suggests entropies of binding are, on average, 23 kJ.mol-1 less 
favourable than binding enthalpies.  Similar trends were found in a smaller set of fragments 
identified in AstraZeneca drug discovery programs. These data also demonstrate that fragment hits 
bind dominantly by favourable enthalpy and this feature can be preserved while they are optimized 
into leads and drug candidates. 
Twelve complexes from the Public dataset, ten complexes of the Astex dataset and one complex 
from the AstraZeneca dataset display positive (unfavourable) binding enthalpies  in Figure 1b and 
Figure 1 panel C.   More information on these complexes is provided in Table 1.  It should be noted 
that data for five of the Astex complexes with unfavourable enthalpy have been omitted from Table I 
since the data were obtained using a displacement ITC experiment format.  In these cases, the 
measured enthalpies also depend on an accurate knowledge of the binding enthalpy of the 
competitor ligand and so may contain larger errors than the complexes measured using direct ITC 
methods.   
The ligands in the 18 complexes of Table I have diverse chemical structures and physico-chemical 
properties that are reasonably representative of a set of drug-like hits and leads, with MWave= 262Da, 
clogPave=1.4 and a calculated charge between +1 and -2.  Similarly, the protein targets are diverse 
and span a number of different target classes, containing the substrate and cofactor binding-sites of 
enzymes, and the protein-protein and protein-small molecule binding domains of recognition 
modules. 
One ligand, present in Astex5 complex, also binds to a second target in the full Astex set with 
Kd~200M and H~-20kJ.mol-1 and so its unfavourable binding enthalpy to target B cannot be 
ascribed to the fragment alone.  Conversely, all of the Astex targets in Table 1 form many complexes 
which have favourable enthalpies and so the observation of an unfavourable enthalpy is also not a 
property of the target alone.   
While the complexes of Table 1 are clearly distinct from the overwhelming majority of  complexes 
described in Figure 1, an understanding of their unusual thermodynamic signatures requires 
additional information which will likely include changes in the protonation and hydration states of 
both the ligand and target when the complex is formed.  It should also be noted that the ligands 
described in Table 1 are not necessarily poor starting points for drug design.  The ligands contained in 
the complexes Astex 2 and Astex 4 were identified by fragment screening of the ATPase domain of 
HSP90 and were starting points for the development of Onalespib (AT13387), a molecule which is 
currently in Phase II clinical trials for cancer [16, 17]. The ligand of Astex 4 complex corresponds to 
compound 19 of ref. 14 and has IE-E = -1.5.  Addition of just two atoms to give compound 30 of ref. 
14, improved its binding affinity by almost 104-fold ,its binding enthalpy by 39kJ.mol-1 and increased 
its enthalpic efficiency to IE-E = 0.5.  Onalespib itself binds to the HSP90 ATPase domain with an 
affinity of 0.7nM, an enthalpy of -41kJ.mol-1 and IE-E = 0.6 [17]. However, it should be stressed that 
such behaviour is unusual: as will be shown below, fragment hits generally have values of IE-E close to 
unity (-TS ~0)  and this value decreases significantly during a typical lead optimisation process. 
 
Further thermodynamic data for several protein targets are available from fragment screening 
campaigns, from fragment optimizations and from systematic analyses of congeneric series described 
in the literature. Panel C of Figure 1 shows target specific binding thermodynamics data that include 
11 fragments tested against trypsin [18], 16 and 7 fragment hits against Mycobacterium tuberculosis 
pantothenate synthetase [19] and PLP-dependent transaminase (BioA) [20], respectively, 58 
fragments screened against p38alpha [21], 11 fragments target Pseudomonas aeruginosa PqsR 
protein [22], 20 congeneric fragments binding to human carbonic anhydrase II [23],  and 4 fragments 
measured by direct ITC against thrombin [24].  All of these 127 fragments bind with favourable 
enthalpy.  More recently we compiled [25] a dataset of 138 neutral fragments (94) and drug like 
compounds (44) acting on 17 targets that showed the pronounced tendency of fragments to bind 
with more favourable enthalpy and less favourable entropy with respect to drug-like compounds 
binding to the same targets (Figure 1, panel E). 
It is important to note that the compounds in ref. 25 were all evaluated by direct ITC measurement 
(92% of the compounds in the dataset show Kd values lower than 100 μM), and no displacement 
experiments were included. A statistical analysis of G,H and –TS values on this dataset showed 
statistically significant difference for the enthalpic and entropic components of fragments and drug-
like compounds (Mann-Whitney U-test, p<0.005). These data also imply that, on average, the relative 
contribution of the enthalpic component to fragment binding, measured using the Enthalpy-Entropy 
index, IE-E, is greater than that observed for drug-like compounds. There is a statistically significant 
difference at the p=0.0009 significance level between the value of IE-E for fragments and drug-like 
compounds with medians 1.10 and 0.79, respectively (Figure 2).    
Similarly to publicly available databases, fragment thermodynamic data from both corporate and 
academic drug discovery laboratories (a total of almost 1000 data points) collected for a wide variety 
of targets show that fragments bind with favourable enthalpy. Moreover, the binding enthalpy 
dominates in the large majority of cases. This clearly distinguishes fragments from larger compounds 
where such preference for enthalpy dominated binding cannot be observed. 
 
Errors in thermodynamic quantities derived from ITC 
In typical ITC experiments used to generate the data described above, a sample of the protein (‘the 
titrand’) is contained within a small reaction cell which is thermally insulated from the environment, 
at the centre of a titration calorimeter.  For typical calorimeters and binding experiments, the protein 
concentration would be 5M to 10M and the cell volume is 0.3ml to 1.5ml.  Small volumes of a 
concentrated solution of the ligand (‘the titrant’) are then added via a syringe, which also serves to 
stir the solution, thus ensuring rapid mixing.  If the ligand binds to the protein with a non-zero 
enthalpy, heat is either released or absorbed, leading to a small temperature change in the cell.   An 
electrical heater is used to maintain a constant temperature difference between the reaction cell and 
a reference cell within the calorimeter, measured using a sensitive thermocouple.  The change in 
heater power required to maintain a fixed temperature difference is then integrated over time and 
the result corresponds to the heat change on ligand binding in the reaction cell.  
Usually, several injections are made to reach a 1:1 stoichiometry of protein and ligand and additional 
injections are then made to ensure that the protein binding site is saturated.  Each injection in the 
first phase releases a small proportion of the binding enthalpy.  For a 1ml cell containing 10M of 
protein with a typical ligand-binding enthalpy of -40kJ.mol-1, each injection releases around 40uJ of 
heat.  To put this in perspective, this is the same amount of heat that would fall on an A4 sheet of 
paper in 1 second, when illuminated by a 40W bulb, placed nearly 5km away. 
It is unsurprising that such calorimetric experiments require sensitive, well-maintained , properly 
calibrated instruments and precisely prepared solutions.  Errors in the molar concentrations of titrant 
or titrand will result in proportionate errors in measured binding enthalpies (H , kJ.mol-1) and 
dissociation constants (Kd , mol.dm-3).  However, since free energies are calculated from the 
logarithm of Kd, the value of G will contain a smaller percentage error.   For example, a 25% error in 
the concentrations would lead to an error of ~5kJ.mol-1 in the calculated molar enthalpy when 
Hbinding = -20kJ.mol-1.  However, a 25% error in Kd only causes an error of 0.6kJ.mol-1 in G, which is 
equivalent to a 2% error in Gbinding when Kd~1M, or a 4% error when Kd~1mM.  Entropies (-TS) 
are calculated as the difference between G and H and so the numerical value of the entropic error 
will closely mirror that of H, with an opposite sign.  This correlation of the errors in H and TS 
measured by ITC is separate from the more familiar enthalpy-entropy compensation, in which 
changes in G usually occur with larger and opposing changes in H and TS [2]. 
Other sources of error or variation must also be recognised and reduced.  Heat may be generated 
simply by the dilution of the titrant into the reaction cell.  This heat of dilution can be estimated from 
injections made after the protein is saturated and must be subtracted from all injection when the 
data are analysed.  Finally changes in the pH or buffer concentration during the course of the 
titration or between experiments can lead to changes in the protonation state of the protein or the 
ligand or their weak interactions with ions in solution.  Both of these events may be associated with 
their own heat changes. 
The practical effects of these errors on measurements of H were investigated at Astex by 
comparing replicate ITC data, obtained from independent ITC experiments over the course of 8 drug 
discovery programs.  An initial search of the Astex database revealed 80 ITC datasets that were part 
of replicate measurements involving 30 unique ligands.  The smallest number of replicate titrations 
was 2 while the largest was 7.  The maximum variation in Hbinding measured from replicate titrations 
for each ligand is illustrated in Figure 3. 
For 70% of the data shown in Figure 3, the variation in H between replicate titrations is better than 
5kJ.mol-1.  However, target 2 and target 4 (CDK2) show some variations that are greater than 
12kJ.mol-1.  In all cases the buffer was unchanged between the replicate titrations.  Closer inspection 
of the database showed that the largest variations between replicate measurements of H involved 
comparisons of different protein constructs (target 2: long +C-terminal tag vs short + N-terminal tag) 
or different protein complexes (target 4: CDK2 vs CDK2.cyclinA). 
After removal of all data involving comparison of different forms of the target (different constructs, 
complexes or phosphorylation states), 56 ITC datasets remained that formed true replicate titrations 
for 22 ligands with 7 protein targets.  Target 5 has no true replicate data; the remaining targets 
contain 2 to 7 replicate titrations.   
The maximum variation in Hbinding measured from true replicate titrations for each ligand is 
illustrated in Figure 4.  This shows that the maximum variation in H observed between true 
replicate titrations for any of the 22 complexes was 5.2kJ.mol-1 and the average of the maximum 
variations was 2.3kJ.mol-1 (S.D. = 1.8kJ.mol-1).   Comparison of Figure 4 with Figure 3 indicates that 
minor modifications to a protein target such as changes in construct length, post-translational 
modifications remote from the ligand binding site and formation of additional protein-protein 
interactions can substantially  change the binding enthalpy of small ligands, here by up to 10kJ.mol-1. 
Although this analysis has focussed on replicate titrations for which the expected difference in H is 
zero, it also indicates that, within the full Astex ITC dataset, errors in H measurements should be 
less than 2.3kJ.mol-1 on average, with 68% having errors less than 4.1kJ.mol-1 and 94% having errors 
less than 5.9kJ.mol-1.  Note that the majority of complexes that are listed in Table 1 have H values 
greater than +5.9kJ.mol-1 and so their unfavourable binding enthalpies are unlikely to be a result of 
experimental error.  
 
Concluding remarks 
Theoretical considerations and experimental data indicate that fragment binding is typically more 
enthalpically-driven than the binding of fragment-derived leads and ligands derived by other drug-
discovery approaches. The average binding enthalpy, measured by calorimetry for a large diverse set 
of fragments and targets, is more favourable than the average binding entropy by an amount that 
agrees well with estimates of the amount of rigid-body entropy that must be surrendered when a 
freely-rotating ligand in solution forms a geometrically-constrained complex with a large molecule. 
Such constraint renders fragments promising starting points for drug discovery programs and creates 
a thermodynamic rationale for fragment based drug discovery. It is important to remember that 
increasing the number and strength of ‘high quality’ interactions such as hydrogen bonds will not 
necessarily result in an overall gain in enthalpy. The measured binding enthalpy is a net value and the 
dissection of the individual contributions might be ambiguous. Solute effects, structural flexibility, 
and cooperativity lead to nonlinear changes in enthalpy and make enthalpy contributions of 
individual intermolecular contacts experimentally non-observable. Binding enthalpy and entropy 
therefore should not be used as direct end points but, together with structural studies and free 
energy calculations, can deepen our understanding of ligand binding [26]. As one designs larger 
molecules, contributions from protein and solvent reorganization are expected to be larger. Enthalpic 
gains are often partially offset by entropic losses as the complex becomes more geometrically 
constrained, and so changes in the enthalpy and entropy of binding tend to be negatively correlated. 
Starting from fragments, it is often possible to efficiently improve the affinity and binding enthalpy 
during early optimization using a combination of structural (primarily X-ray) and thermodynamic (ITC) 
data.  
The association of enthalpic interactions with ‘high-quality’ binding in drug discovery has a number of 
origins.  Firstly, the optimisation of geometrically constrained interactions favours the use of 
structure-based design which, when combined with computational methods in iterative cycles of 
synthesis and testing, restricts the number of chemical targets and improves the efficiency of the 
process.  Secondly, the incorporation of more geometrical constraints into the interaction also 
provides a simple rationale to predict and possibly improve the selectivity of binding of a ligand to a 
related set of protein targets. Thirdly, the improvement of affinity using entropic gains is most closely 
associated with an increase in the lipophilicity of the ligand and the subsequent burial of 
hydrophobic surface area on binding.  This has traditionally led to the generation of drug candidates 
of high molecular weight (500Da) with poor solubility and which also bind non-specifically to cell 
membranes and transport proteins.  This often leads to low efficacy and the observation of metabolic 
liabilities in clinical trials and has been described as ‘molecular obesity’ [27].  
The small size and low lipophilicity of a well-designed fragment library provide a large operational 
freedom to optimize fragment hits into development candidates with beneficial physicochemical and 
ADME properties, as demonstrated by recent FBDD success stories [28].  Furthermore, the 
requirement for libraries to be tested at high concentrations and therefore to have good aqueous 
solubilities favours fragments that contain several hydrogen-bond donors and acceptors.  Since 
fragment screening also explores chemical space efficiently and usually generates multiple, 
chemically diverse hits, the tendency for them to be geometrically-constrained by hydrogen-bonds 
allows the most common, and hence favourable, interactions with the protein to be identified and 
probed using new molecules that were not part of the initial screening set.  This merging or growing 
of fragment hits is proving to be a fruitful stimulus for the synthesis of novel, small heterocycles and 
other chemical entities. 
The tendency for fragment binding to be associated with a gain in enthalpy should not be translated 
into dogma.  We have shown examples of two fragments which bind to their target protein, HSP90, 
with unfavourable enthalpies but favourable entropies, although this situation was rapidly reversed 
in the course of their initial optimisation using structure-based design.  This is not a common 
occurrence amongst the targets studied to date; the favourable entropy of binding of these fragment 
hits probably has its origin in the release of several protein-bound water molecules from the active 
site which form part of a network of hydrogen bonds used to recognise the purine base of its 
cofactor, ATP.  However, these fragments led to the development of a drug-candidate, so such hits 
should not be overlooked.  
When modifications to the ligand improve H but with no change in G, there is still the prospect of 
further increases in affinity, provided the concurrent change in binding entropy can be addressed. In 
these circumstances, attention might first focus on restricting the conformation of the free ligand or 
preserving some flexibility in the protein-ligand complex.     
In drug design, optimisation will require compromises between, for example, potency, safety, cellular 
activity and pharmacodynamic efficacy.  Compounds that interact with high specificity with their 
target will nevertheless stand the best chance of success. A key feature of fragment binding is the 
identification of near-optimal geometries for polar interactions. The better our understanding of the 
biophysical parameters involved, the better able we will be to guide drug design towards safe and 
efficacious compounds.  
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Figure legends 
 
Figure 1 Binding thermodynamics data for fragments 
 
Panel A: Hbinding vs –TSbinding for a structurally diverse set of fragments available from the 
Scorpio, PDBCal and BindingDB databases 
 
Panel B: (Hbinding+ TSbinding)  vs Gbinding for the same set of structurally diverse fragments 
available from Scorpio, PDBCal and BindingDB databases.  Note that the change of axes 
corresponds to a 45 degree rotation of the data in panel A and would allow areas containing no 
data points to be discarded (G<-60kJ.mol-1 and G>0kJ.mol-1).   
 
panel C: Fragment thermodynamics data from drug discovery programs (blue: Astex, red 
AstraZeneca) 
 
panel D: Fragments from screening efforts against different targets (green: pantothenate 
synthetase, light blue: P38alpha, orange: carbonic anhydrase, red: trypsin, black: PLP-dependent 
transaminase, light green: thrombin, dark red: Pqsr) 
 
panel E: Enthalpic and entropic components of binding for complexes of neutral fragments and 
drug-like molecules  
 
 
Figure 2 Distribution and statistics of binding enthalpy (H), binding entropy (-TS) and (H+TS)/G 
for neutral fragments and drug-like compounds measured by direct ITC experiments. The analysis 
considered 94 fragments and 44 drug-like compounds acting on 17 protein targets [25]. Mann-
Whitney U-test was applied to test the difference between fragments and drug-like compounds.  The 
results show that fragments bind with more favourable enthalpy (p=0.0001) and less favourable 
entropy (p=0.0016) with respect to drug-like compounds.  Furthermore, the scaled difference 
between enthalpy and entropy of binding ((H+TS)/G) demonstrates the increased importance of 
enthalpy gain for fragment binding. The box plots show the median within the box of the 1st and 3rd 
quartiles together with the range of non-outlier data defined as 1.5 fold the interquartile range 
around the median. 
 
 
 
  
Figure 3  Variation in Hbinding for apparent replicate titrations within the Astex database.  80 ITC 
datasets contribute to this comparison of complexes between 8 protein targets and 30 ligands.  The 
average variation between these apparent replicates is 4.7kJ.mol-1 
 
Figure 4  Variation in Hbinding for true replicate titrations within the Astex database.  The average 
variation between these true replicates is 2.3kJ.mol-1.  Target numbering is the same as in Figure 3.  
Target 5 had no true replicate data and is not present in this figure. 
 
Table 1 Properties of ligands and targets in Figure 1 (panels B and C) which have unfavourable 
binding enthalpies 
 
  
Authors 
 
Glyn Williams 
Glyn Williams joined Astex in 2001, to develop and apply biophysical methods to fragment-based 
screening and drug design.  This work has involved the use of Nuclear Magnetic Resonance, 
Isothermal Titration Calorimetry and native Mass Spectrometry and also contributed to the 
development the Astex fragment library.  He is the Vice President, Biophysics of Astex 
Pharmaceuticals. Previously Glyn had spent 11 years with Roche UK where he was responsible for 
biological NMR and analytical Mass Spectrometry.  After obtaining his degree and doctorate (DPhil.) 
in Chemistry from the University of Oxford, Glyn held fellowships and lectureships in Inorganic and 
Bio-Inorganic chemistry at the Universities of Oxford, Sydney and London from 1983 to 1990. 
 
 
György Ferenczy 
György G. Ferenczy received his PhD in computational chemistry from the Eötvös University of 
Budapest. Following postdoctoral research at the University of Oxford, UK and at the University of 
Nancy, France, he worked as a computational chemist and as a group leader first at Gedeon Richter 
(Budapest) and later at Sanofi (Budapest and Strasbourg). Since 2012, he is a senior research fellow 
at the Semmelweis University and from 2013 at the RCNS of the Hungarian Academy of Sciences. His 
research interest includes the development and application of computational tools for extended 
biochemical systems and studying molecular interactions relevant to drug discovery. 
 
 
Johan Ulander 
Johan Ulander currently works as Associate Principal Scientist in the computational chemistry section 
at Cardiovascular and Metabolic Diseases (CVMD) at AstraZeneca R&D Göteborg, Sweden. Prior to 
joining AstraZeneca he did post-doctoral research at University of California, San Diego (USCD) and 
University of Houston. He received his PhD in theoretical physical chemistry from Gothenburg 
University and has a B.Sc. in Molecular Biology from the University of Umeå, Sweden. He has over 10 
years of experience in drug discovery from early stage hit and target identification to late stage drug 
optimization. His interests include theoretical biophysics and statistical mechanics with applications 
in drug design, pharmacokinetics and pharmacodynamics. 
 
 
György M. Keserű 
György M. Keserű obtained his Ph.D. at Budapest, Hungary and joined Sanofi-Aventis CHINOIN, 
heading a chemistry research lab. He moved to Gedeon Richter in 1999 as the Head of Computer-
Aided Drug Discovery. Since 2007, he was appointed as the Head of Discovery Chemistry at Gedeon 
Richter and contributed to the discovery of the antipsychotic VraylarTM (cariprazine) that has been 
approved and marketed in the United States from 2016. From 2013, he served as a director general 
of the Research Center for Natural Sciences (RCNS) at the Hungarian Academy of Sciences. Now he is 
heading the Medicinal Chemistry Research Group at RCNS. His research interests include medicinal 
chemistry and drug design. He has published over 180 papers and more than 15 books and book 
chapters. 
 
  
Highlights 
 A large thermodynamic dataset has been analyzed, containing binding data for 1364 
complexes from Astex, AstraZeneca, Pfizer and academic labs. 
 We demonstrate that unlike many drug-like compounds in the existing public databases, 
fragments bind enthalpically to their protein targets. 
 This observation provides an insight into the thermodynamic consequences of fragment 
based drug discovery and suggests a thermodynamic rationale for prioritising compounds 
which may form key interactions with a high degree of specificity.” 
